Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice

Tomoyuki Homma; Noriyo Nagata; Masayuki Hashimoto; Naoko Iwata-Yoshikawa; Naomi M. Seki; Nozomi Shiwa-Sudo; Akira Ainai; Keiji Dohi; Eiji Nikaido; Akiko Mukai; Yuuta Ukai; Takayuki Nakagawa; Yusuke Shimo; Hiroki Maeda; Seiki Shirai; Miwa Aoki; Takuhiro Sonoyama; Mamoru Sato; Masataka Fumoto; Morio Nagira; Fumihisa Nakata; Takao Hashiguchi; Tadaki Suzuki; Shinya Omoto; Hideki Hasegawa

doi:10.1038/s41598-022-25418-5

Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice

Tomoyuki Homma, Noriyo Nagata, Masayuki Hashimoto, Naoko Iwata-Yoshikawa, Naomi M. Seki, Nozomi Shiwa-Sudo, Akira Ainai, Keiji Dohi, Eiji Nikaido, Akiko Mukai, Yuuta Ukai, Takayuki Nakagawa, Yusuke Shimo, Hiroki Maeda, Seiki Shirai, Miwa Aoki, Takuhiro Sonoyama, Mamoru Sato, Masataka Fumoto, Morio NagiraFumihisa Nakata, Takao Hashiguchi, Tadaki Suzuki, Shinya Omoto, Hideki Hasegawa

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Vaccines that efficiently target severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent for coronavirus disease (COVID-19), are the best means for controlling viral spread. This study evaluated the efficacy of the COVID-19 vaccine S-268019-b, which comprises the recombinant full-length SARS-CoV-2 spike protein S-910823 (antigen) and A-910823 (adjuvant). In addition to eliciting both Th1-type and Th2-type cellular immune responses, two doses of S-910823 plus A-910823 induced anti-spike protein IgG antibodies and neutralizing antibodies against SARS-CoV-2. In a SARS-CoV-2 challenge test, S-910823 plus A-910823 mitigated SARS-CoV-2 infection-induced weight loss and death and inhibited viral replication in mouse lungs. S-910823 plus A-910823 promoted cytokine and chemokine at the injection site and immune cell accumulation in the draining lymph nodes. This led to the formation of germinal centers and the induction of memory B cells, antibody-secreting cells, and memory T cells. These findings provide fundamental property of S-268019-b, especially importance of A-910823 to elicit humoral and cellular immune responses.

Original language	English
Article number	20861
Journal	Scientific Reports
Volume	12
Issue number	1
DOIs	https://doi.org/10.1038/s41598-022-25418-5
State	Published - Dec 2022
Externally published	Yes

Access to Document

10.1038/s41598-022-25418-5

Cite this

Homma, T., Nagata, N., Hashimoto, M., Iwata-Yoshikawa, N., Seki, N. M., Shiwa-Sudo, N., Ainai, A., Dohi, K., Nikaido, E., Mukai, A., Ukai, Y., Nakagawa, T., Shimo, Y., Maeda, H., Shirai, S., Aoki, M., Sonoyama, T., Sato, M., Fumoto, M., ... Hasegawa, H. (2022). Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice. Scientific Reports, 12(1), Article 20861. https://doi.org/10.1038/s41598-022-25418-5

@article{64804c45384d44e787a0f5d3fa9df351,

title = "Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice",

abstract = "Vaccines that efficiently target severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent for coronavirus disease (COVID-19), are the best means for controlling viral spread. This study evaluated the efficacy of the COVID-19 vaccine S-268019-b, which comprises the recombinant full-length SARS-CoV-2 spike protein S-910823 (antigen) and A-910823 (adjuvant). In addition to eliciting both Th1-type and Th2-type cellular immune responses, two doses of S-910823 plus A-910823 induced anti-spike protein IgG antibodies and neutralizing antibodies against SARS-CoV-2. In a SARS-CoV-2 challenge test, S-910823 plus A-910823 mitigated SARS-CoV-2 infection-induced weight loss and death and inhibited viral replication in mouse lungs. S-910823 plus A-910823 promoted cytokine and chemokine at the injection site and immune cell accumulation in the draining lymph nodes. This led to the formation of germinal centers and the induction of memory B cells, antibody-secreting cells, and memory T cells. These findings provide fundamental property of S-268019-b, especially importance of A-910823 to elicit humoral and cellular immune responses.",

author = "Tomoyuki Homma and Noriyo Nagata and Masayuki Hashimoto and Naoko Iwata-Yoshikawa and Seki, {Naomi M.} and Nozomi Shiwa-Sudo and Akira Ainai and Keiji Dohi and Eiji Nikaido and Akiko Mukai and Yuuta Ukai and Takayuki Nakagawa and Yusuke Shimo and Hiroki Maeda and Seiki Shirai and Miwa Aoki and Takuhiro Sonoyama and Mamoru Sato and Masataka Fumoto and Morio Nagira and Fumihisa Nakata and Takao Hashiguchi and Tadaki Suzuki and Shinya Omoto and Hideki Hasegawa",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

doi = "10.1038/s41598-022-25418-5",

language = "English",

volume = "12",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

number = "1",

}

Homma, T, Nagata, N, Hashimoto, M, Iwata-Yoshikawa, N, Seki, NM, Shiwa-Sudo, N, Ainai, A, Dohi, K, Nikaido, E, Mukai, A, Ukai, Y, Nakagawa, T, Shimo, Y, Maeda, H, Shirai, S, Aoki, M, Sonoyama, T, Sato, M, Fumoto, M, Nagira, M, Nakata, F, Hashiguchi, T, Suzuki, T, Omoto, S & Hasegawa, H 2022, 'Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice', Scientific Reports, vol. 12, no. 1, 20861. https://doi.org/10.1038/s41598-022-25418-5

TY - JOUR

T1 - Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice

AU - Homma, Tomoyuki

AU - Nagata, Noriyo

AU - Hashimoto, Masayuki

AU - Iwata-Yoshikawa, Naoko

AU - Seki, Naomi M.

AU - Shiwa-Sudo, Nozomi

AU - Ainai, Akira

AU - Dohi, Keiji

AU - Nikaido, Eiji

AU - Mukai, Akiko

AU - Ukai, Yuuta

AU - Nakagawa, Takayuki

AU - Shimo, Yusuke

AU - Maeda, Hiroki

AU - Shirai, Seiki

AU - Aoki, Miwa

AU - Sonoyama, Takuhiro

AU - Sato, Mamoru

AU - Fumoto, Masataka

AU - Nagira, Morio

AU - Nakata, Fumihisa

AU - Hashiguchi, Takao

AU - Suzuki, Tadaki

AU - Omoto, Shinya

AU - Hasegawa, Hideki

PY - 2022/12

Y1 - 2022/12

N2 - Vaccines that efficiently target severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent for coronavirus disease (COVID-19), are the best means for controlling viral spread. This study evaluated the efficacy of the COVID-19 vaccine S-268019-b, which comprises the recombinant full-length SARS-CoV-2 spike protein S-910823 (antigen) and A-910823 (adjuvant). In addition to eliciting both Th1-type and Th2-type cellular immune responses, two doses of S-910823 plus A-910823 induced anti-spike protein IgG antibodies and neutralizing antibodies against SARS-CoV-2. In a SARS-CoV-2 challenge test, S-910823 plus A-910823 mitigated SARS-CoV-2 infection-induced weight loss and death and inhibited viral replication in mouse lungs. S-910823 plus A-910823 promoted cytokine and chemokine at the injection site and immune cell accumulation in the draining lymph nodes. This led to the formation of germinal centers and the induction of memory B cells, antibody-secreting cells, and memory T cells. These findings provide fundamental property of S-268019-b, especially importance of A-910823 to elicit humoral and cellular immune responses.

AB - Vaccines that efficiently target severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent for coronavirus disease (COVID-19), are the best means for controlling viral spread. This study evaluated the efficacy of the COVID-19 vaccine S-268019-b, which comprises the recombinant full-length SARS-CoV-2 spike protein S-910823 (antigen) and A-910823 (adjuvant). In addition to eliciting both Th1-type and Th2-type cellular immune responses, two doses of S-910823 plus A-910823 induced anti-spike protein IgG antibodies and neutralizing antibodies against SARS-CoV-2. In a SARS-CoV-2 challenge test, S-910823 plus A-910823 mitigated SARS-CoV-2 infection-induced weight loss and death and inhibited viral replication in mouse lungs. S-910823 plus A-910823 promoted cytokine and chemokine at the injection site and immune cell accumulation in the draining lymph nodes. This led to the formation of germinal centers and the induction of memory B cells, antibody-secreting cells, and memory T cells. These findings provide fundamental property of S-268019-b, especially importance of A-910823 to elicit humoral and cellular immune responses.

UR - http://www.scopus.com/inward/record.url?scp=85143213277&partnerID=8YFLogxK

U2 - 10.1038/s41598-022-25418-5

DO - 10.1038/s41598-022-25418-5

M3 - Article

C2 - 36460696

AN - SCOPUS:85143213277

SN - 2045-2322

VL - 12

JO - Scientific Reports

JF - Scientific Reports

IS - 1

M1 - 20861

ER -

Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice

Abstract

Access to Document

Fingerprint

Cite this